Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT
Open Access
- 9 May 2016
- Vol. 6 (5), e010703
- https://doi.org/10.1136/bmjopen-2015-010703
Abstract
Objective To quantify the journeys and CO2 emissions if women with breast cancer are treated with risk-adapted single-dose targeted intraoperative radiotherapy (TARGIT) rather than several weeks' course of external beam whole breast radiotherapy (EBRT) treatment. Setting (1) TARGIT-A randomised clinical trial (ISRCTN34086741) which compared TARGIT with traditional EBRT and found similar breast cancer control, particularly when TARGIT was given simultaneously with lumpectomy, (2) 2 additional UK centres offering TARGIT. Participants 485 UK patients (249 TARGIT, 236 EBRT) in the prepathology stratum of TARGIT-A trial (where randomisation occurred before lumpectomy and TARGIT was delivered simultaneously with lumpectomy) for whom geographical data were available and 22 patients treated with TARGIT after completion of the TARGIT-A trial in 2 additional UK breast centres. Outcome measures The shortest total journey distance, time and CO2 emissions from home to hospital to receive all the fractions of radiotherapy. Methods Distances, time and CO2 emissions were calculated using Google Maps and assuming a fuel efficiency of 40 mpg. The groups were compared using the Student t test with unequal variance and the non-parametric Wilcoxon rank-sum (Mann-Whitney) test. Results TARGIT patients travelled significantly fewer miles: TARGIT 21 681, mean 87.1 (SE 19.1) versus EBRT 92 591, mean 392.3 (SE 30.2); had lower CO2 emissions 24.7 kg (SE 5.4) vs 111 kg (SE 8.6) and spent less time travelling: 3 h (SE 0.53) vs 14 h (SE 0.76), all p2 per patient). Conclusions The use of TARGIT intraoperative radiotherapy for eligible patients with breast cancer significantly reduces their journeys for treatment and has environmental benefits. If widely available, 5 million miles (8 000 000 km) of travel, 170 000 woman-hours and 1200 tonnes of CO2 (a forest of 100 hectares) will be saved annually in the UK. Trial registration number ISRCTN34086741; Post-results.Keywords
This publication has 23 references indexed in Scilit:
- Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel DistanceJournal of Clinical Oncology, 2015
- Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialThe Lancet, 2014
- Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statisticsBMJ, 2012
- Why do hospital mastectomy rates vary? Differences in the decision-making experiences of women with breast cancerBritish Journal of Cancer, 2011
- Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO)International Journal of Radiation Oncology*Biology*Physics, 2009
- Tackling Climate Change Close to Home: Mobile Breast Screening as a ModelJournal of Health Services Research & Policy, 2009
- Travel time to radiotherapy and uptake of breast-conserving surgery for early stage cancer in Northern EnglandHealth & Place, 2008
- Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancerEuropean Journal Of Cancer, 2008
- The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancerEuropean Journal of Surgical Oncology, 2002
- Carbon sequestration in the trees, products and soils of forest plantations: an analysis using UK examplesTree Physiology, 1992